CN110730663A - 阿帕替尼和c-Met抑制剂联合在制备治疗肿瘤的药物中的用途 - Google Patents
阿帕替尼和c-Met抑制剂联合在制备治疗肿瘤的药物中的用途 Download PDFInfo
- Publication number
- CN110730663A CN110730663A CN201880035052.9A CN201880035052A CN110730663A CN 110730663 A CN110730663 A CN 110730663A CN 201880035052 A CN201880035052 A CN 201880035052A CN 110730663 A CN110730663 A CN 110730663A
- Authority
- CN
- China
- Prior art keywords
- cancer
- tumor
- inhibitor
- use according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
阿帕替尼和c‑Met抑制剂联合在制备治疗肿瘤的药物中的用途。阿帕替尼与化合物(1)或其可药用盐联合在制备治疗肿瘤的药物中的用途。
Description
PCT国内申请，说明书已公开。
Claims (16)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710865846 | 2017-09-22 | ||
| CN2017108658465 | 2017-09-22 | ||
| PCT/CN2018/106878 WO2019057141A1 (zh) | 2017-09-22 | 2018-09-21 | 阿帕替尼和c-Met抑制剂联合在制备治疗肿瘤的药物中的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110730663A true CN110730663A (zh) | 2020-01-24 |
| CN110730663B CN110730663B (zh) | 2022-09-16 |
Family
ID=65810092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880035052.9A Active CN110730663B (zh) | 2017-09-22 | 2018-09-21 | 阿帕替尼和c-Met抑制剂联合在制备治疗肿瘤的药物中的用途 |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN110730663B (zh) |
| TW (1) | TWI685341B (zh) |
| WO (1) | WO2019057141A1 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114028586A (zh) * | 2021-11-25 | 2022-02-11 | 南昌大学附属口腔医院(江西省口腔医院) | 一种基于pdx模型研究阿帕替尼抗肿瘤作用效果的方法 |
| CN115120731A (zh) * | 2022-07-12 | 2022-09-30 | 四川大学华西医院 | 一种靶向蛋白酶体治疗乳腺癌的药物应用 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110292578A (zh) * | 2019-08-13 | 2019-10-01 | 厦门大学附属第一医院 | 阿帕替尼在制备治疗急性髓系白血病的药物中的新应用 |
| CN115919741B (zh) * | 2021-08-24 | 2024-02-27 | 北京理工大学 | 一种阿帕替尼肛门栓剂及其制备方法 |
| CN113855710B (zh) * | 2021-10-09 | 2024-02-20 | 施慧达药业集团(吉林)有限公司 | 戈氏梭菌联合肿瘤血管生成抑制剂的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012044577A1 (en) * | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
| WO2014180182A1 (zh) * | 2013-05-10 | 2014-11-13 | 江苏豪森药业股份有限公司 | [1,2,4]三唑并[4,3-a]吡啶类衍生物，其制备方法或其在医药上的应用 |
-
2018
- 2018-09-21 CN CN201880035052.9A patent/CN110730663B/zh active Active
- 2018-09-21 WO PCT/CN2018/106878 patent/WO2019057141A1/zh active Application Filing
- 2018-09-21 TW TW107133335A patent/TWI685341B/zh not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012044577A1 (en) * | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
| WO2014180182A1 (zh) * | 2013-05-10 | 2014-11-13 | 江苏豪森药业股份有限公司 | [1,2,4]三唑并[4,3-a]吡啶类衍生物，其制备方法或其在医药上的应用 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114028586A (zh) * | 2021-11-25 | 2022-02-11 | 南昌大学附属口腔医院(江西省口腔医院) | 一种基于pdx模型研究阿帕替尼抗肿瘤作用效果的方法 |
| CN115120731A (zh) * | 2022-07-12 | 2022-09-30 | 四川大学华西医院 | 一种靶向蛋白酶体治疗乳腺癌的药物应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019057141A1 (zh) | 2019-03-28 |
| TW201914592A (zh) | 2019-04-16 |
| CN110730663B (zh) | 2022-09-16 |
| TWI685341B (zh) | 2020-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110730663B (zh) | 阿帕替尼和c-Met抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| WO2022052874A1 (zh) | 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用 | |
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| TWI762784B (zh) | Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途 | |
| KR20220003560A (ko) | 유잉 육종의 치료를 위한 퀴놀린 화합물 또는 그의 약제학적으로 허용 가능한 염 | |
| CN112043702A (zh) | 用于联合治疗结直肠癌的喹啉类化合物 | |
| CN110650741A (zh) | 用于治疗结直肠癌的喹啉衍生物 | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| CN113811298B (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| CN112043831A (zh) | 用于联合治疗乳腺癌的喹啉类化合物 | |
| TW201536319A (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| CN113840608B (zh) | Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| EP3973963A1 (en) | Quinoline derivatives for treatment of head and neck cancer | |
| JP2014034531A (ja) | Ｈｓｐ９０阻害剤とゲムシタビンの組み合わせ | |
| WO2020228656A1 (zh) | 用于联合治疗软组织肉瘤的喹啉衍生物 | |
| Cheke et al. | Biologicals and small molecules as target-specific cancer chemotherapeutic agents | |
| CN114191558A (zh) | Egfr抑制剂与抗血管新生药物在治疗肿瘤疾病的药物中的用途 | |
| JP2014034534A (ja) | ＨＳＰ９０阻害剤とｍＴＯＲ阻害剤の組み合わせ | |
| CN113797342A (zh) | 用于预防或治疗肿瘤疾病的治疗剂组合 | |
| CN115779095A (zh) | 治疗结直肠癌的喹啉衍生物与pd-1单抗的药物组合 | |
| CN112294814A (zh) | 用于治疗胶质母细胞瘤的喹啉衍生物 | |
| CN118159538A (zh) | 含met受体酪氨酸激酶抑制剂的药物组合及应用 | |
| JP2014034535A (ja) | Ｈｓｐ９０阻害剤とｖｅｇｆｒチロシンキナーゼ且つｐｄｇｆチロシンキナーゼ阻害剤の組み合わせ | |
| NZ786609A (en) | Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer | |
| JP2014034532A (ja) | Ｈｓｐ９０阻害剤と抗ｈｅｒ２抗体の組み合わせ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |